Literature DB >> 1834180

Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromes.

S Jost1, C Reuner, J Geiger, M Mohadjer, E Milios, H Cramer.   

Abstract

Substance P-like and somatostatin-like immunoreactivities (SPLI and SLI) were determined in ventricular fluid of patients with chronic pain syndromes and in a comparison group with multiple sclerosis, essential tremor, epilepsy and postanoxic myoclonus. Concentrations of SPLI and SLI were non-significantly decreased by 40% and 33% in chronic pain patients as compared with control patients without pain. There were no differences apparent between subgroups of pain patients (deafferentation pain, neoplasia-induced pain, thalamic pain). High pressure liquid chromatography combined with radioimmunoassay showed marked heterogeneity of SPLI and SLI.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834180     DOI: 10.1007/bf02191152

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  24 in total

1.  Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn.

Authors:  Y Kuraishi; N Hirota; Y Sato; Y Hino; M Satoh; H Takagi
Journal:  Brain Res       Date:  1985-01-28       Impact factor: 3.252

2.  A study of beta-endorphin and substance P level in cerebrospinal fluid on lumbar lesion.

Authors:  K Masaki
Journal:  Tokushima J Exp Med       Date:  1987-12

3.  Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in chronic pain patients.

Authors:  Bruno J Urban; Randal D France; Garth Bissette; Fred J Spielman; Charles B Nemeroff
Journal:  Pain       Date:  1988-05       Impact factor: 6.961

4.  Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.

Authors:  H Cramer; K Rissler; N Rösler; D Strubel; D Schaudt; F Kuntzmann
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

5.  Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease.

Authors:  H Cramer; N Rösler; K Rissler; M C Gagnieu; B Renaud
Journal:  Neuropeptides       Date:  1988-10       Impact factor: 3.286

6.  Somatostatin, a potent analgesic.

Authors:  J Chrubasik; J Meynadier; S Blond; P Scherpereel; E Ackerman; M Weinstock; K Bonath; H Cramer; E Wünsch
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

7.  Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli.

Authors:  M Randić; V Miletić
Journal:  Brain Res       Date:  1978-08-18       Impact factor: 3.252

8.  Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.

Authors:  A R Doran; D R Rubinow; O M Wolkowitz; A Roy; A Breier; D Pickar
Journal:  Biol Psychiatry       Date:  1989-02-15       Impact factor: 13.382

9.  Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.

Authors:  J G Nutt; E A Mrox; S E Leeman; A C Williams; W K Engel; T N Chase
Journal:  Neurology       Date:  1980-12       Impact factor: 9.910

10.  Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord.

Authors:  V J Massari; C W Shults; C H Park; Y Tizabi; T W Moody; B M Chronwall; M Culver; T N Chase
Journal:  Brain Res       Date:  1985-09-23       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.